Unified Patent Court

Fujifilm Files Patent Infringement Lawsuit Against Eastman Kodak Company

Retrieved on: 
Wednesday, March 20, 2024
Fujifilm, Patent, Kodak, District court, KODK, Research, Sale, Unified Patent Court, Investment, 3D printing

HANOVER PARK, Ill., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation, Graphic Communication Division today announced that FUJIFILM Corporation filed a patent infringement lawsuit against Eastman Kodak Company (NYSE: KODK) in the United States District Court for the District of New Jersey.

Key Points: 
  • HANOVER PARK, Ill., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation, Graphic Communication Division today announced that FUJIFILM Corporation filed a patent infringement lawsuit against Eastman Kodak Company (NYSE: KODK) in the United States District Court for the District of New Jersey.
  • Fujifilm has asserted four patents (U.S. Patent Nos.
  • 10,427,443, 10,525,696, 10,875,346, and 11,294,279) pertaining to various aspects of processless lithographic printing plate technologies, including method and apparatus claims.
  • “We will enforce and protect our innovation and intellectual property rights in the United States and around the world when we believe others infringe unfairly.”
    Separately in October 2023 and December 2023 respectively, Eastman Kodak’s European subsidiaries, Kodak GmbH, Kodak Graphic Communications GmbH, and Kodak Holding GmbH, were sued by FUJIFILM Corporation for infringement of the related European counterparts of the US patents-in-suit in the Unified Patent Court and in Germany.

Innovation in Healthcare and Digital Technologies Boosts European Patent Applications by U.S. Companies

Retrieved on: 
Tuesday, March 19, 2024
Boston Scientific, Growth, Biotechnology, Unitary, Unitary patent, Environment, EPO, Medtronic, Unified Patent Court, Samsung, Johnson & Johnson, European Patent Convention, Invention, Patent, Ericsson, South Korea, Multimedia, SME

MUNICH, March 19, 2024 /PRNewswire/ -- U.S. companies filed 48 155 patent applications at the European Patent Office last year, an increase of 0.4% compared to 2022, according to the EPO's Patent Index 2023 .

Key Points: 
  • MUNICH, March 19, 2024 /PRNewswire/ -- U.S. companies filed 48 155 patent applications at the European Patent Office last year, an increase of 0.4% compared to 2022, according to the EPO's Patent Index 2023 .
  • The U.S. thus accounted for 24.2% of the total patent applications received by the EPO in 2023.
  • The U.S. consistently ranks as the top filing country at the EPO, and the number of patent applications has increased by +31.3% since 2014.
  • The U.S. growth was driven by increased patent applications in healthcare and digital technologies, making up the five leading U.S technology fields with the most patent applications in Europe: medical technology (6 098 patent applications), computer technology (5 111), digital communication (5 008), pharmaceuticals (3 802), biotechnology (2 751).

Iridex Corporation Receives European Patent on MicroPulse Technology

Retrieved on: 
Tuesday, February 6, 2024
Paratriathlon, Commitment, Glaucoma, Ophthalmology, Safety, European Patent Convention, Unified Patent Court, Laser, IRIX, Retina, Unitary patent, Risk, Medical imaging

This groundbreaking patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments.

Key Points: 
  • This groundbreaking patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments.
  • Iridex is the exclusive provider of MicroPulse® devices that utilize the patented technology.
  • In European countries the Unitary Patent will be enforced by members of the Unified Patent Court as well as the United Kingdom.
  • A Commitment to Advancing Medical Laser Treatments "This advancement enhances both the safety and effectiveness of laser treatments in ophthalmology and the patent grant affirms our exclusive position as the only authorized provider of MicroPulse technology," stated David Bruce, President and CEO of Iridex Corporation.

South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain

Retrieved on: 
Wednesday, November 1, 2023
Female, FDA, White Light Rock & Roll Review, Aes, Patent, Neuropathic pain, Wireless ambulatory ECG, U.S. Patent No. 1, Fast Track, Liver, MAD, Kidney, EPO, Volunteering, Priority review, Male, NSAIDS, Unified Patent Court, European Patent Office, PK, Accelerated approval (FDA), New Drug Application, Pain, Liver failure, Nonsteroidal anti-inflammatory drug, OBI Pharma, Inc., NDA, Fast track (FDA), Safety, Vital signs, Paracetamol, European Patent Convention, Plasma protein binding, Pharmaceutical industry, EU

NEW ORLEANS, Nov. 1, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company focused on developing innovative pain treatments, announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023. This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.

Key Points: 
  • This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.
  • This patent, excluding possible patent term extensions, is expected to provide South Rampart with market exclusivity in the EPO member states until 2038, aligning with the U.S. Patent No.
  • On October 4, 2023, the U.S. FDA granted Fast Track designation to SRP-001 for acute pain.
  • The FDA Fast Track designation allows for more frequent interactions with the FDA, streamlining the clinical development plan and trial design to expedite drug approval.

Wolters Kluwer adds new Unified Patent Court Case Law Tracker to Kluwer IP Law

Retrieved on: 
Thursday, September 28, 2023
Visser, EPC, UPC, IP, Unitary patent, Patent, Unified Patent Court, Wolters Kluwer, News

NEW YORK, Sept. 28, 2023 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. has updated its award-winning intellectual property rights and registration solution Kluwer IP Law with the addition of an intuitive UPC Case Law Tracker. Customers will be able to track patent decisions made by the newly operational Unified Patent Court (UPC) that determine the infringement and validity of both Unitary Patents and classic European Patents.

Key Points: 
  • NEW YORK, Sept. 28, 2023 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. has updated its award-winning intellectual property rights and registration solution Kluwer IP Law with the addition of an intuitive UPC Case Law Tracker.
  • The UPC Case Law Tracker is a part of Kluwer IP Law's UP/UPC Hub, a vital source for industry developments, news, and key commentaries from leading experts.
  • Kluwer IP Law is Wolters Kluwer's premier service focused on all key IP law, providing legal professionals with quick answers and expert commentary from prominent practitioners and thought leaders.
  • Kluwer IP Law also provides users with key EPC sources for European patent attorneys, such as Visser's Annotated European Patent Convention and the PCT Practice and Strategy work.

10x Wins Injunction From Unified Patent Court Banning Sales of NanoString's CosMx Products in Europe

Retrieved on: 
Tuesday, September 19, 2023
Patent, NanoString Technologies, Genomics, Federal Patent Court (Germany), 10x Genomics, SMI, UPC, Palatine Higher Regional Court, Research, RNA, Science, Invention, Rosenbergia xenium, District court, Investment, Patient, European, Unified Patent Court, European Patent Convention, Court, Health, Douglas v. U.S. District Court ex rel Talk America, Disease, Alex Cartana, Microscope

PLEASANTON, Calif., Sept. 19, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") issued a preliminary injunction against NanoString Technologies, Inc. (Nasdaq: NSTG) for infringing European Patent 4 108 782 B1 ("the EP 782 patent," docket No 459746/2023). The preliminary injunction, issued by a panel of four judges with both legal and technical expertise, prevents NanoString from selling or providing services using its CosMx Spatial Molecular Imager (SMI) instruments and CosMx reagents for RNA detection in all 17 countries of the UPC.

Key Points: 
  • "A patent holder must meet a very high standard to win a preliminary injunction," added Whitaker.
  • "Two separate courts have now found that NanoString's CosMx products infringe two different 10x patents, and three separate courts have preliminarily found the 10x patents valid in the asserted scope.
  • The full opinions of the Unified Patent Court will be posted here when available: 10xgen.com/munich-spatial-news .
  • 10x also intends to seek an injunction against sales of GeoMx as well as ongoing damages.

Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe

Retrieved on: 
Wednesday, June 7, 2023
Neurology, Biotechnology, Oncology, Patent Law, Health, Infectious Diseases, Professional Services, Genetics, Genomics, 10x Genomics, UPC, Research, Harvard University, Sale, Friends, District court, Unified Patent Court, NanoString Technologies, Douglas v. U.S. District Court ex rel Talk America, Pharmaceutical industry

Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe.

Key Points: 
  • Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe.
  • Dear Customers, Researchers and Friends of Vizgen:
    We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers.
  • Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more.
  • At Vizgen, we believe that researchers should have the ability to choose the best technologies that help advance science, discovery, and human health.

10x Genomics Files Two New Lawsuits Requesting Preliminary Injunctions Against NanoString's CosMx Products

Retrieved on: 
Thursday, June 1, 2023
Unified Patent Court, Federal Patent Court (Germany), NanoString Technologies, Genomics, SMI, UPC, RNA, Judgement, Patent, Microscope, EU

PLEASANTON, Calif., June 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it filed new patent litigation against NanoString Technologies, Inc. (Nasdaq: NSTG) and Vizgen, Inc. in the European Unified Patent Court. 

Key Points: 
  • 10x Genomics' new lawsuits allege that the use and distribution of NanoString's CosMx products for RNA detection infringe European Patents 2 794 928 B1 ("the EP 928 patent") and 4 108 782 B1 ("the EP 782 patent").
  • 10x Genomics also filed suit against Vizgen's MERSCOPE products for infringement of the EP 782 patent.
  • In its new lawsuits against NanoString before the Munich Local Division of the Unified Patent Court, 10x Genomics is seeking preliminary injunctions against NanoString's CosMx Spatial Molecular Imager (SMI) instruments and CosMx reagents for RNA detection in the jurisdictions of the Unified Patent Court in which the EP 928 and EP 782 patents are in effect.
  • In February 2023, the German Federal Patent court issued a preliminary opinion finding the asserted claims of the EP 928 patent valid.

Seoul Semiconductor Obtains Permanent Injunction Against Various LED Products for Patent Infringement in Europe

Retrieved on: 
Thursday, May 18, 2023
Automotive Manufacturing, Consumer Electronics, Technology, Manufacturing, Professional Services, Patent Law, Environmental, Social and Governance (ESG), Other Technology, Other Manufacturing, Legal, Hardware, Intellectual property, Light-emitting diode, Semiconductor, Oberlandesgericht, Culture, German, Osram, Palatine Higher Regional Court, Multimedia, Unitary patent, LED, KOSDAQ, Patent, Unified Patent Court, Supreme court, Seoul Semiconductor, ESG, Generic drug

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced on May 16 that the Higher Regional Court in Düsseldorf, Germany, issued a final judgement confirming a permanent injunction for infringement of Seoul’s patent against multiple LED companies' LEDs.

Key Points: 
  • Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced on May 16 that the Higher Regional Court in Düsseldorf, Germany, issued a final judgement confirming a permanent injunction for infringement of Seoul’s patent against multiple LED companies' LEDs.
  • View the full release here: https://www.businesswire.com/news/home/20230518005058/en/
    Seoul Semiconductor's patent technology applied to various solutions (Graphic: Seoul Semiconductor Co., Ltd.)
    The permanent injunction judgement extends to LED products from Everlight Electronics Co., Ltd., which were distributed globally through Mouser Electronics Inc., as well as LED products from LED Engin merged into Osram GmbH.
  • Under this new system, patent infringement judgements from the Unified Patent Court will simultaneously take effect in 17 European countries, including Germany, France, and Italy.
  • As a result, Seoul and its affiliates have obtained 14 permanent injunction judgements against manufacturers and distributors of infringing products in the U.S. and Europe over the past five years.

MaxVal Announces Support for Unitary Patent within Symphony IP Management System

Retrieved on: 
Tuesday, February 7, 2023
Organization, Unitary patent, Video news release, Unified Patent Court, EPO, API, Release, UPC, IP, EU, LOS, Generic drug, Symphony

LOS ALTOS, Calif., Feb. 7, 2023 /PRNewswire/ -- MaxVal Group, Inc. ("MaxVal"), one of the leading end-to-end intellectual property product and solutions providers, today announced their IP management system, Symphony, will now enable customers to effectively and seamlessly manage the imminent introduction of Unitary Patents and the Unified Patent Court in Europe.

Key Points: 
  • New Release includes additional workflows, country rules, jurisdictions, and automated opt-out to support changes arising from the new Unitary Patent and Unitary Patent Court
    LOS ALTOS, Calif., Feb. 7, 2023 /PRNewswire/ -- MaxVal Group, Inc. ("MaxVal"), one of the leading end-to-end intellectual property product and solutions providers, today announced their IP management system, Symphony, will now enable customers to effectively and seamlessly manage the imminent introduction of Unitary Patents and the Unified Patent Court in Europe.
  • The Unified Patent system puts an end to costly parallel litigation and enhances legal certainty.
  • The Unitary Patent and the UPC are the building blocks that will supplement and strengthen the existing centralized European patent granting system.
  • With the latest enhancements to Symphony, MaxVal's Symphony IP management system will now feature UPC jurisdictions and related information, a new case type for patent records related to the Unitary Patent, country rules, built-in workflows, and dashboards to track Unitary Patent requests.